Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
New York, January 14, 2026, 14:14 EST — Regular session Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak. The gain bucked a softer market. The Invesco QQQ Trust, a proxy for the Nasdaq 100, was down about 1.5%, while the SPDR S&P 500 ETF…